Alkermes, Elan in $960 million merger
Alkermes, Elan in $960 million merger
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
The $960 million merger between Elan Drug Technologies and Alkermes is discussed. The merger enables Alkermes to offer a slow-release system not only for small molecules but also for biologic drugs. For Elan, the cash infusion will reduce its considerable debts and enable the biotech to focus on developing drugs for neurological disorders.
Alternative Titles
Full title
Alkermes, Elan in $960 million merger
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_883016619
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_883016619
Other Identifiers
ISSN
1087-0156
E-ISSN
1546-1696
DOI
10.1038/nbt0711-559b
